
Iovance Biotherapeutics Q3 Earnings Exceed Expectations – A Buying Opportunity
Iovance Biotherapeutics Q3 Earnings Review Introduction Iovance Biotherapeutics recently announced their Q3 earnings, which outperformed expectations with $58.6 million in revenue. Despite this positive news, the company’s shares fell due to high market expectations and concerns about competition in the industry. Overview of Amtagvi Amtagvi, Iovance’s lead drug, has shown strong commercial potential. The company…